C. Giessen

发表

Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial

U. Mansmann, V. Heinemann, R. Laubender, 2013, Acta oncologica.

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2011, British Journal of Cancer.

Resection of Pulmonary Metastases from Colon and Rectal Cancer: Factors to Predict Survival Differ Regarding to the Origin of the Primary Tumor

A. Crispin, M. Stemmler, V. Heinemann, 2014, Annals of Surgical Oncology.

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2014, Journal of Cancer Research and Clinical Oncology.

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.

V. Heinemann, W. Schmiegel, R. Porschen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

V. Heinemann, A. Wollenberg, J. Neumann, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3

V. Heinemann, S. Ormanns, S. Holdenrieder, 2015, Tumor Biology.

NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response predominantly in patients with intestinal type tumors

V. Heinemann, A. Wein, K. Ridwelski, 2015, International journal of cancer.

LBA11INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION

W. Scheithauer, V. Heinemann, T. Decker, 2014 .

O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

Deepness of response: A quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC.

U. Mansmann, V. Heinemann, R. Laubender, 2013 .

Improved early prediction of individual prognosis for patients with mCRC: Joint modeling of tumor shrinkage with volume data for PFS and OS.

A. Graser, U. Mansmann, V. Heinemann, 2012 .

Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC).

U. Mansmann, V. Heinemann, R. Laubender, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.

M. Stauch, V. Heinemann, H. Hass, 2012 .

Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status

S. Stintzing, D. Modest, C. Giessen, 2012 .

Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group

V. Heinemann, A. Wollenberg, J. Neumann, 2013, International journal of cancer.

Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib

V. Heinemann, Yan Wang, Yüe Zhao, 2015, Anti-cancer drugs.

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

V. Heinemann, J. Neumann, T. Kirchner, 2012, International journal of cancer.

Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis

V. Heinemann, W. Schmiegel, A. Tannapfel, 2012, Anti-cancer drugs.

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status

V. Heinemann, J. Neumann, T. Kirchner, 2011, Anti-cancer drugs.

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

V. Heinemann, S. Boeck, A. Schalhorn, 2009, World journal of gastroenterology.

Primary effusion lymphoma (PEL) without effusion: a patient case report of a PEL solid variant

A. Rosenwald, A. Graser, V. Heinemann, 2011, Journal of Clinical Pathology.

Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trial

V. Heinemann, S. Stintzing, L. Fischer von Weikersthal, 2013, Cancer science.

Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer

V. Heinemann, P. Stieber, F. Spelsberg, 2014, Tumor Biology.

Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels

V. Heinemann, S. Stintzing, S. Boeck, 2013, Anti-cancer drugs.

Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials

D. Ankerst, U. Mansmann, V. Heinemann, 2015, Acta oncologica.

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

D. Ankerst, U. Mansmann, V. Heinemann, 2012, Clinical Cancer Research.

Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

V. Heinemann, S. Stintzing, A. Schalhorn, 2014, Anti-cancer drugs.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.

W. Scheithauer, V. Heinemann, T. Decker, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial

V. Heinemann, R. Laubender, S. Stintzing, 2013, British Journal of Cancer.

Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC.

U. Mansmann, V. Heinemann, R. Laubender, 2013 .

Course of calcium and magnesium serum levels in cetuximab-treated patients: Relation to concurrent chemotherapy and possible predictive value.

V. Heinemann, S. Stintzing, D. Modest, 2013 .

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

M. Bangerter, A. Hinke, V. Heinemann, 2011, BMC Cancer.

Combined resection of colorectal hepatic–pulmonary metastases shows improved outcome over chemotherapy alone

A. Crispin, V. Heinemann, R. Hatz, 2013, Langenbeck's Archives of Surgery.

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

M. Stauch, V. Heinemann, D. Oruzio, 2011, European journal of cancer.

Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy

V. Heinemann, R. Laubender, M. Michl, 2014, Tumor Biology.

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, M. Stauch, V. Heinemann, 2015 .

Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases.

V. Heinemann, W. Schmiegel, A. Tannapfel, 2012, Journal of Clinical Oncology.

Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.

D. Ankerst, V. Heinemann, R. Laubender, 2011, Clinical colorectal cancer.

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

C. Giessen, C. Schulz, M. Haas, 2012, International journal of cancer.